$118.8 B

LLY Mkt cap, 15-Oct-2018

Eli Lilly Revenue

Eli Lilly revenue was $21.22 b in FY, 2016 which is a 6.3% year over year increase from the previous period.

Embed Graph

Eli Lilly Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1b19.6b20.0b21.2b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9b4.9b5.0b5.7b

Gross profit

18.2b14.7b14.9b15.6b

Gross profit Margin, %

79%75%75%73%

Pre tax profit

5.9b3.0b2.8b3.4b

Income tax expense

1.2b609.8m381.6m636.4m

Net Income

4.7b2.4b2.4b2.7b

Quarterly

USDQ1, 2018

Revenue

5.7b

Pre tax profit

1.4b

Eli Lilly Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8b3.9b3.7b4.6b

Accounts Receivable

588.4m566.7m558.6m736.9m

Inventories

2.9b2.7b3.4b3.6b

Current Assets

13.1b12.2b12.6b15.1b

PP&E

8.0b8.0b8.1b8.3b

Goodwill

1.8b4.0b4.0b

Total Assets

35.2b37.2b35.6b38.8b

Accounts Payable

1.1b1.1b1.3b1.3b

Dividends Payable

523.5m530.3m539.0m548.1m

Current Liabilities

8.9b11.2b8.2b11.0b

Long-term debt

4.2b5.4b8.0b8.4b

Total Debt

4.2b5.4b8.0b8.4b

Common Stock

698.5m694.6m691.3m

Additional Paid-in Capital

5.1b5.3b5.6b5.6b

Retained Earnings

17.0b16.5b16.0b16.0b

Total Equity

17.6b15.4b14.6b14.1b

Debt to Equity Ratio

0.2 x0.3 x0.5 x0.6 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x0.2 x

Financial Leverage

2 x2.4 x2.4 x2.8 x

Quarterly

USDQ1, 2018

Current Liabilities

11.5b

Additional Paid-in Capital

5.8b

Eli Lilly Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7b2.4b2.4b2.7b

Cash From Operating Activities

5.7b4.4b2.8b4.9b

Purchases of PP&E

(1.0b)(1.2b)(1.1b)(1.0b)

Cash From Investing Activities

(2.1b)(3.9b)26.8m(3.1b)

Short-term Borrowings

2.7b(2.7b)1.3b

Long-term Borrowings

(10.5m)(1.0b)(2.0b)(200.0k)

Dividends Paid

(2.1b)(2.1b)(2.1b)(2.2b)

Cash From Financing Activities

(3.8b)(75.1m)(2.9b)(559.8m)

Quarterly

USDQ2, 2018

Depreciation and Amortization

848.0m

Cash From Operating Activities

2.0b
Report incorrect company information

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Report incorrect company information